瑞替普酶辅助治疗急性心肌梗死临床效果及预后情况观察.docVIP

精品论文 参考文献 瑞替普酶辅助治疗急性心肌梗死临床效果及预后情况观察 秦朝霞 　　冀中能源峰峰集团总医院急诊科 河北邯郸 056200 　　【摘 要】目的：评价与分析ST段抬高性急性心肌梗死患者采用瑞替普酶与尿激酶治疗疗效及安全性，并观察患者预后。方法：90例ST段抬高性急性心肌梗死患者按照随机数字表法分为对照组与观察组，各45例。对照组采用尿激酶150万U溶栓治疗；观察组采用瑞替普酶18mg静脉注射，30min内再次注射1次。比较2组患者血管再通率及心血管事件发生率、死亡情况。结果：观察组30min血管再通率与对照组比较(Pgt;0.05)；观察组60min、90min、120min血管再通率与对照组比较(Plt;0.05)。观察组出血率和死亡率分别为4.44%(2/45)、2.22%(1/45)与对照组15.56%(7/45)、 8.89%(4/45)比较(Plt;0.05)。2组心血管事件发生率比较(Pgt;0.05)。结论：相比尿激酶来说，采用瑞替普酶治疗ST段抬高性急性心肌梗死患者可提高患者血管再通，减少临床出血率和死亡率，具有较高安全性和有效性，值得进一步研究与推广。 　　【关键词】瑞替普酶；尿激酶；ST段抬高性；急性心肌梗死 　　【中图分类号】R542.2 【文献标识码】B 【文章编号】1674-8999（2015）9-0665-02 　　Reteplase acute myocardial infarction observed clinical effects of adjuvant therapy and prognosis 　　【Abstract】objective：Evaluation and analysis of patients with acute ST-segment elevation myocardial infarction using reteplase and urokinase treatment efficacy and safety, and to observe the patient prognosis.Methods：90 cases of patients with ST-segment elevation acute myocardial infarction according to the random number table divided into a control group and observation group, 45 cases each. The control group was 1.5 million U of urokinase thrombolytic therapy; observation group reteplase 10mu intravenous injection once again after 30min. Comparison of two groups of patients recanalization rate and incidence of cardiovascular events and death situation.Results：30min observation group recanalization rates compared with control group (Pgt; 0.05); observation group 60min, 90min, 120min recanalization rates compared with control group (P lt;0.05). Bleeding and mortality rate in the observation group were 4.44% (2/45), 2.22% (1/45) and the control group 15.56% (7/45), 8.89% (4/45) Comparison (P lt;0.05). Two groups the incidence of cardiovascular events (Pgt; 0.05).Conclusion：Compared with urokinase for further research and the use of reteplase treatment of patients with acute ST-segment elevation myocardial infarction patients can improve recanalization, reduce clinical bleeding and mor